Last reviewed · How we verify

Roxacin — Competitive Intelligence Brief

Roxacin (ROXITHROMYCIN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: roxithromycin. Area: Infectious Disease.

marketed roxithromycin Motilin receptor, 50S ribosomal protein L10, Alpha-1B adrenergic receptor Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Roxacin (ROXITHROMYCIN). Roxithromycin works by binding to the bacterial ribosome and inhibiting protein synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Roxacin TARGET ROXITHROMYCIN marketed roxithromycin Motilin receptor, 50S ribosomal protein L10, Alpha-1B adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (roxithromycin class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Roxacin — Competitive Intelligence Brief. https://druglandscape.com/ci/roxithromycin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: